Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

Status Terminated

Clinical Trial Summary

Herpes zoster (commonly referred to as "shingles") results from the reactivation of the varicella-zoster virus acquired during a primary infection, usually chickenpox. The virus lays dormant in the cells of the nerves until activated. Once activated, patients develop a characteristic red blistering rash which crusts and heals in 2 - 4 weeks. Postherpetic neuralgia (PHN), the term for pain persisting after the herpes zoster (HZ) eruption heals, is the most common and most feared complication of herpes zoster infection. The drug, Civamide is thought to desensitize the nerves and decrease the pain of PHN. This is the pharmacologic rationale for its use in the nose in postherpetic neuralgia of the trigeminal nerve, a nerve that is in the nose and transmits pain from the face. The objective of this study is to evaluate the safety and efficacy of intranasally administered Civamide (0.01%) for the treatment of moderate to severe daily pain associated with postherpetic neuralgia of the trigeminal nerve. Neuropathic pain must have persisted for ≥ 12 months.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01886313
Study type	Interventional
Source	Winston Laboratories
Contact
Status	Terminated
Phase	Phase 2
Start date	March 2014
Completion date	April 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04546334` - Erector Spinae Plane Block in Post-herpetic Neuralgia	N/A
Terminated	`NCT01744522` - Leech Therapy for Postherpetic Neuralgia	N/A
Completed	`NCT01688947` - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)	Phase 2
Completed	`NCT00478179` - Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia	Phase 2
Completed	`NCT00566904` - New Topical Treatment for Continued Pain After Shingles	Phase 1
Completed	`NCT04099706` - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT	N/A
Terminated	`NCT01603394` - Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia	Phase 4
Completed	`NCT01228838` - Study of NGX-1998 for the Treatment of Postherpetic Neuralgia	Phase 2
Completed	`NCT01251211` - Botulinum Toxin in Peripheral Neuropathic Pain	Phase 4
Completed	`NCT00612105` - Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)	Phase 2
Recruiting	`NCT04560361` - The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia	N/A
Recruiting	`NCT05568186` - Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
Recruiting	`NCT04664530` - The Study on the Esketamine in the Treatment of Postherpetic Neuralgia	Phase 4
Active, not recruiting	`NCT01508676` - Effects of Pennsaid on Clinical Neuropathic Pain	N/A
Completed	`NCT00885586` - Acupuncture in Herpes Zoster Neuralgia (ACUZoster)	Phase 4
Completed	`NCT00981227` - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia	Phase 2
Completed	`NCT00576108` - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)	Phase 2
Completed	`NCT00238511` - An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN)	Phase 2
Completed	`NCT00007501` - Shingles Prevention Study	Phase 3
Completed	`NCT04594226` - Electroacupuncture Therapy for Treating Postherpetic Neuralgia	N/A